SinoWise Pharmaceutics Limited

华药君康有限公司

Developing and commercializing innovative Chinese Medicine and small-molecule therapeutics based on clinical data and experience

About Us

SinoWise Pharmaceutics Limited (hereinafter referred to as SinoWise) was established in October 2022 as a spin-off company from the Center for Chinese Herbal Medicine Drug Development Limited (CDD), which is funded by the Hong Kong Government's Innovation and Technology Commission under the Health@InnoHK program.

SinoWise aims to develop and commercialize innovative Chinese Medicine and small-molecule therapeutics based on clinical data and experience, addressing unmet clinical needs. SinoWise has received funding from Hong Kong Science Park's Incu-Bio program and moved into Science Park Building 17W in June 2024.

Technology Platforms

Clinical Data-Driven Innovative Chinese Medicine R&D Platform

AI-Driven Small-molecule Therapeutics R&D Platform

Unique Advantages

1. Expert Leadership

Founder Professor Bian Zhaoxiang is a Chair Professor at the School of Chinese Medicine, Hong Kong Baptist University, and the inaugural CEO of Hong Kong's first Chinese Medicine Hospital. He is a pioneer in Chinese Medicine research and development in Hong Kong with an excellent track record in innovative Chinese Medicine development.

2. Clinical Data Driven

A clinical data-driven R&D platform that reduces trial-and-error costs and significantly improves clinical trial success rates.

3. Dual Regulatory Advantage

Innovative drugs derived from Chinese Medicine herbs can be developed as botanical/small-molecule drugs under Western regulatory agencies (e.g. FDA) or as traditional Chinese Medicine/small-molecule drugs under Chinese regulatory agencies (e.g. NMPA), maximizing market potential.

4. Focused Therapeutic Areas

Focusing on unmet clinical needs in autoimmune, cardiovascular, and gastrointestinal area, with future priority access to clinical-stage products from CDD.

Product Pipeline

SWP-2194

Psoriasis Treatment

Status: Completed Preclinical Candidate Compound (PCC) nomination, IND-enabling studies ongoing

SWP-2198

Dilated Cardiomyopathy Treatment

Status: Small molecule drug derived from Chinese herbs, novel mechanism and structure oral drug, in drug discovery phase

Contact Us

Address:

Room 640, 6/F, Building 17W, No. 17 Science Park West Avenue, Pak Shek Kok, Shatin, Hong Kong

Email:

info@sinowise.net

Tel:

Coming Soon